{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-012342","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.326337+00:00","generated_at":"2026-06-04T04:26:00.481562+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"INVO Bioscience enters $850K equity purchase agreement with Triton Funds, issues warrants at $2.00/share","bullets":["Up to 1,000,000 shares at $0.85/share sold to Triton, aggregate proceeds capped at $850,000.","Private placement warrants for 1,000,000 shares at $2.00/share, immediately exercisable, expire in 5 years.","Purchase agreement expires Dec 31, 2024; Triton obligated to buy on Company's request but no shorting allowed.","Until shareholder approval, shares issued limited to 523,344 (19.9% of outstanding common stock) under Nasdaq rules.","Proceeds used for general corporate purposes; warrants unregistered and no trading market expected."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-012342","json":"https://secwatch.observer/filing/0001493152-24-012342.json","markdown":"https://secwatch.observer/filing/0001493152-24-012342.md","text":"https://secwatch.observer/filing/0001493152-24-012342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012342/0001493152-24-012342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012342/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:26:00.481562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"921c16b98bd1ec6dab4ddb58cf0877147fdceb69","claim":"INVO Fertility, Inc. entered into Purchase Agreement with Triton Funds LP valued at up to $850,000 (effective 2024-03-27).","evidence_excerpt":"On March 27, 2024, INVO Bioscience, Inc., a Nevada corporation (the “ Company ”) entered into a purchase agreement (the “ Purchase Agreement ”) with Triton Funds LP (“ Triton ”), pursuant to which the Company agreed to sell, and Triton agreed to purchase, upon the Company’s request in one or more transactions, up to 1,000,000 shares of the Company’s common stock, par value $0.0001 per share, providing aggregate gross proceeds to the Company of up to $850,000.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315224012342/0001493152-24-012342-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Triton Funds LP"},{"label":"Value","value":"up to $850,000"},{"label":"Effective","value":"2024-03-27"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}